Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Sees Large Decrease in Short Interest

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 180,500 shares, a decline of 32.6% from the January 15th total of 267,900 shares. Based on an average daily volume of 138,100 shares, the short-interest ratio is presently 1.3 days.

Medexus Pharmaceuticals Stock Performance

Shares of Medexus Pharmaceuticals stock traded down $0.04 during trading on Friday, reaching $2.17. The company’s stock had a trading volume of 15,435 shares, compared to its average volume of 52,415. The stock has a 50-day moving average price of $2.48 and a two-hundred day moving average price of $2.04. Medexus Pharmaceuticals has a one year low of $1.08 and a one year high of $3.88.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.